Physician profile
Laura Downing
NPI 1053677716
$13,393.17
in general payments reported to CMS, 2019-2025
34 companies · $9,954 in 2025
The $9,954 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $311 · 2021: $834 · 2022: $746 · 2023: $542 · 2024: $558 · 2025: $9,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,600 · Food and Beverage: $1,354 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,600.00 |
| Food and Beverage | $1,353.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $9,600.00 | 2025 | Ardeograft, Renograft, Vitograft |
| Abbvie INC. | $741.33 | 2019-2023 | Liletta |
| Exeltis, USA INC. | $494.04 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $405.80 | 2022-2025 | |
| Therapeuticsmd, INC. | $300.01 | 2019-2022 | |
| Astellas Pharma US INC | $274.27 | 2021-2024 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $238.27 | 2021-2024 | Sos, Summit Doppler, Paragard T 380a |
| Hologic Sales and Service, LLC | $164.68 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Biogen, INC. | $157.69 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $154.25 | 2021-2024 | Phexxi |
| Pacira Pharmaceuticals Incorporated | $117.99 | 2019 | |
| Organon LLC | $110.45 | 2021-2024 | Nexplanon |
| Agile Therapeutics, INC. | $93.15 | 2021-2022 | |
| Avion Pharmaceuticals | $92.25 | 2019-2022 | |
| Myovant Sciences INC. | $65.74 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $58.25 | 2024 | Irrisept |
| Millicent US INC | $44.99 | 2024-2025 | Intrarosa |
| Lupin INC. | $41.50 | 2020-2021 | |
| Mission Pharmacal Company | $40.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.71 | 2019 | |
| Currax Pharmaceuticals LLC | $28.58 | 2024-2025 | Contrave, Onzetra Xsail |
| Allergan, INC. | $26.87 | 2019-2020 | |
| Shield Therapeutics INC | $19.01 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.51 | 2019 | |
| Davol INC. | $14.99 | 2023 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $14.60 | 2020 | |
| Duchesnay USA Incorporated | $13.19 | 2019 | |
| Minerva Surgical, INC | $11.44 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.